A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas
Blood-based tumor DNA testing now rivals tissue biopsies at detecting a key aggressive lymphoma risk factor, offering patients a simpler alternative.
In 123 uniformly treated high-risk LBCL patients, targeted ctDNA duplex sequencing reliably captured copy number aberrations and outperformed conventional FISH for TP53 loss-based risk stratification. These findings validate ctDNA-based CNA profiling as a minimally invasive alternative to tissue-based molecular testing in aggressive lymphoma.
What the study was
- Study design
- Prospective cohort with validation cohort
- Population
- Patients with high-risk large B-cell lymphoma (LBCL) receiving uniform treatment
- Sample size
- 123
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Leukemia
Why it surfaced
Leukemia journal; n=123 prospective cohort with independent validation; ctDNA CNA profiling outperforms FISH for TP53 risk stratification in LBCL; clinically actionable and near-implementable liquid biopsy result.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.